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Abstract Background The Nef protein of HIV-1 is suspected to play a role in the depletion of
uninfected CD4þ lymphocytes that leads to AIDS. By contrast its effect on CD8þ cells,
whose functions are also deregulated during HIV-1 infection, is presently unclear. Here we
describe a number of derangements induced in vitro by Nef in CD8þ cells from HIV-1-
infected patients.
Design Peripheral lymphocytes from 16 HIV-1þ subjects and 9 uninfected individuals
were cultivated on a Nef-transfected mouse fibroblast layer exposing the carboxyl-terminal
region of the viral protein on cell membrane. The cultures were then measured for both
apoptosis and proliferation by subdiploid DNA content and Ki67 expression, respectively,
whereas the molecular analysis of purified CD8þ cells investigated the Fas-L mRNA levels
in Nef-treated CTLs. In addition, we evaluated the Nef-induced variation in the extent of
CD8þ/HLA-DRþ subset, which includes non cytotoxic cells secreting T-cell antiviral factor
(CAF) and a soluble factor inhibiting the HIV-1 replication.
Results The viral protein induced in peripheral blood lymphocytes (PBL) a moderate
tendency to proliferate, as measured by the increment of Ki67 antigen, particularly on the
CD8þ subset of HIV-1 infected individuals (P <0·05). This profile was particularly evident
in cultures from patients with severe CD4þ lymphopenia and paralleled an apparent
expansion of the CD8þ/CD57þ suppressor cell subset. Molecular analysis of purified
CD8þ cells revealed a defective expression of Fas-L mRNA in Nef-cultured CTLs, whereas
the viral protein exerted a down modulatory effect on the CD8þ/HLA-DRþ subset
(P <0·05), thus suggesting a potential inhibition of CAF.
Conclusions These results support a potential role of Nef in the progression of HIV-1
infection as a number of cellular functions are affected in the CD8þ subset. In particular, the
defective functions of CD8þ cells induced by the viral protein could contribute, at least
partly, to the escape of HIV-1 from the immune control of these cells.
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Introduction
Both the human (HIV-1) and the simian (SIV) immuno-
deficiency viruses are complex retroviruses whose genomes
comprise many regulatory genes, namely tat, rev, vif, vpu,
nef, vpr and vpx [1,2]. Among them, vif, vpu, vpr and nef
are not needed for virus replication in vitro and are there-
fore termed ‘nonessential’ [3].
The nef gene is located at the 30 of env gene and partially
overlaps the U3 region of the 30 LTR. The product of
HIV-1 nef is a 27–30 kDa protein whose myristoylation at
its N-terminus [4] permits its linkage to the cytoplasmic
leaflet of the plasma membrane. However, perturbation
of the lipid bilayers by the myristoylated protein also leads
the carboxyl-terminal portion of Nef to protrude on the
cell membrane [5]. Even so, infected lymphocytes usually
express Nef in both their cytosol and nuclei and may also
solubilize the protein by the cell membrane [6–8].
The biological role of Nef on HIV-1 replication is
controversial. In contrast to its in vitro inefficacy [9–12],
recent studies have shown that the intact nef gene is
pivotal in maintaining a high virus load in rhesus monkeys
infected with the pathogenic SIVmac239 clone, and for
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the development of AIDS [13]. In addition, the wild-type
nef gene from HIV-1 significantly increases the viral load in
the SCID-Hu mouse model (a severe combined immuno-
deficient mouse transplanted with human fetal liver and
thymus) [14], whereas its mutated form showing a struc-
tural defect in 30 LTR sequences has been tentatively
associated with long-term non-progression of the disease
in HIV-1 infected subjects [15]. These observations sug-
gested that nef gene and its product could be involved in the
lymphocyte depletion that leads to AIDS. Demonstration
of the suppressive effect of Nef on T-cell activation as well
as the inhibition of CD4þ cell growth [16] and the down-
regulation of both TCR-induced IL-2 production [17], and
activation of transcriptional factors NF-kB and AP-1 [18]
has lent support to this interpretation. In addition, Th1
cytokine secretion is specifically suppressed in T cells incu-
bated with Nef protein, whereas Th2 production is scarcely
affected [19].
Nef may directly exert a cytotoxic effect on CD4þ cells
by inducing their apoptosis [20,21], just as env [22] and tat
[23] promote this in T cells and contribute to the devel-
opment of CD4þ lymphopenia. This hypothesis is sup-
ported by suppression of the in vitro proliferation of
CD4þ cells and the fact that membrane expression of the
C–terminus domain of Nef in infected lymphocytes
cocultured with unprimed T-cell lines activates their suici-
dal death [20,21,24]. Further investigations have suggested
that the Nef-induced down-regulation of CD4 molecules
correlates with the intracellular levels of Nef [25], whereas
its apoptogenic effect on T and B cells, macrophages and
neutrophils during HIV-1 infection is apparently unrelated
to the CD95/Fas pathway [26,27]. Conversely, soluble Nef
has been shown to induce considerable cellular activation
as a result of its superantigen effect on MHC class II
molecules [28,29].
This work studied the effect of Nef on peripheral lym-
phocytes from HIV-1 infected individuals at different
stages. CD4þ cells were clearly affected and underwent a
variable degree of suppression, whereas CD8þ cells showed
an apparent increase in their proliferative rate, especially
the CD8þ/CD57þ cells which exhibit a prevalently sup-
pressor phenotype. In addition, Nef inhibited both the
expression of Fas-L on cytotoxic CD8þ cells and the pro-
liferation of HLA-DRþ lymphocytes, namely a population
that suppresses HIV-1.
Methods
Plasmid construction
Full-length nef was amplified from pNL4–3 (kindly pro-
vided by Dr M. Federico, Laboratory of Virology, Istituto
Superiore di Sanita`, Rome, Italy) by polymerase chain
reaction (PCR) using the primer pair covering the ATG
and the ‘stop codon’ of the native nef sequence [4]. The
amplification employed 25 cycles at 94 8C for 450 0,
58 8C for 300 0 and 72 8C for 3000, respectively. The PCR
product was then purified and cloned into pTracer eukary-
otic expression vector (Invitrogen, Pero, Italy) to create
pTracer-nef.
Cell lines and transfection procedures
In preparing the feeder layer expressing Nef for human
lymphocyte cultures, we adopted a xenogeneic adherent
cell line to avoid molecular interactions between syngeneic
human cells potentially perturbing the cellular response.
Therefore, we used the NIH-3T3 cells, a fibroblast line
established from NIH Swiss mouse embryo cultures
(ATCC, Rockville, Maryland, USA), which have been
successfully employed in transfection studies exploring
the response of human NK cells [30]. The 3T3 cells were
grown in DMEM (at high glucose rate) medium supple-
mented with 10% FCS and L-glutamine and subsequently
transfected with 5 mg of pTracer-nef by Lipofectamine
(Gibco-BRL, Life Technologies Italia, San Giuliano
Milanese, Italy) according to the manufacturer’s instruc-
tions. After appropriate selection in G418 at 1 mg mL¹1,
single clones were isolated and further analysed by
RT-PCR to assess the quantitative expression of nef. We
then selected nine clones showing high levels of nef
RT-PCR product as evaluated by direct O.D. measurement
after extraction from agarose gel (ConcertTM Gel Extrac-
tion Kit, Gibco BRL, Milan, Italy). In addition, the mem-
brane expression of Nef was estimated by flow cytometry
with the anti-Nef monoclonal antibody (MoAb) AE6
(obtained from ‘AIDS Research and Reference Reagent
Program’, Division of AIDS, NIAD, NIH, Bethesda
MA, USA). Four clones (3T3–2, ¹3, ¹5, and ¹7) were
positive for high membrane expression of Nef as demon-
strated by a relative fluorescence intensity higher than
one decade. Comparative experiments in preliminary
tests in which peripheral blood lymphocytes (PBL) were
incubated with each of the Nef-positive transfectants
showed a major suppressive effect on CD8þ subsets by
the 3T3–7 transfectant. As the protein was expressed on
the membrane of more than 95% of cells in this clone, we
used the 3T3–7 transformant as adherent layer to culture
lymphocytes.
PBL purification and coculturing with
Nef-transfected cells
The study included 16 HIV-1 infected patients at different
disease stages and 9 healthy donors. Seven patients were
arbitrarily considered as severely lymphopenic (CD4þ cells
#300 mL¹1). PBL were purified from heparinized blood
using Ficoll Hypaque gradient centrifugation and subse-
quent removal of adherent cells by incubation for 45 min
at 37 8C. The cells were then washed and cultured at
1 · 106 mL¹1 in 6-well plates containing the adherent
3T3–7 at 50–60% of confluency in RPMI-1640 plus
10% FCS in the presence of 1mg mL¹1 interleukin (IL)-2.
After 60 h of coculture, the nonadherent cells were
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harvested, washed and used for further analysis. To pro-
perly evaluate the effect of Nef, cellular analyses were
compared in all instances to parallel cultures from each
PBL sample of both patients and controls using non-
transfected 3T3 cells as substrate.
Measurement of proliferation and apoptosis in cells
stimulated by Nef
Proliferation was assessed by double fluorescence measure-
ment of the expression of Ki67 antigen, in association
with subset phenotyping with specific MoAbs to CD4,
CD8, and CD16 antigens (Becton-Dickinson, Mountain
View, CA, USA). Double fluorescence was also used to
measure the size of the CD8þ/CD57þ subset in response
to Nef. To evaluate apoptosis, cells were harvested and
permeabilized by 70% ethanol for 1 h at þ4 8C prior to
staining with propidium iodide at 50 mg mL¹1 in PBS
to detect subdiploid DNA [31,32]. The extent of apoptosis
was then expressed as the percentage of cells with sub-
diploid DNA. These analyses were conducted in a FACS-
can (Becton-Dickinson) using the CellQuest program.
Preparation of purified CD8þ cell suspension and
phenotype analysis
The effect of Nef on T-cell subsets was examined by
purifying CD8þ subsets from each PBL sample preincu-
bated with nef-transfected cells and the relative control
by immunomagnetic isolation using Dynabeads M-450
(Unipath, Milan, Italy). The full procedure recommended
by the manufacturer was employed, providing a final
enrichment of 92·3% of CD8þ cells. Double fluorescence
analysis then evaluated the expression of HLA-DR anti-
gens, which define the activated phenotype of CD8þ cells
as response to the incubation with Nef.
Molecular analyses
In view of the proliferative response of CD8þ cells to Nef,
we measured the expression of Fas-L mRNA in purified
CD8þ populations, because Fas-L is a prevalent marker
of cytotoxic cells (CTL) within this subset. Thus, mRNA
was isolated from 1 · 106 CD8þ cells in both unstimulated
and Nef-stimulated cultures from 11 patients by the guani-
dium thiocyanate-cesium chloride procedure (Invitrogen,
Celbio, Pero, Italy), and transcribed into first-strand
cDNA with the Boehringer-Mannheim (Milan, Italy)
cDNA kit. The Fas-L wild-type-specific primers were
designed in relation to the known gene structure as
follows: 50-GCC CAA GCT TGA AGC AGC CCT-30
(FW), and 50-TGC TGT GTG CAT CTG GTC GGT
AGA-30 (RV) related to the exon-2 of the gene. Both
primers and cDNA from each CD8þ preparation were
added to the PCR mixture (Perkin-Elmer, Cetus, Norwalk,
Connecticut, USA) with subsequent amplification in a
thermal cycler for 35 cycles (1 min 94 8C, 1 min 65 8C,
1 min 72 8C) and the Fas-L PCR product was visualized
on a 1·5 agarose gel with ethidium bromide. Fas-L mRNA
was estimated by evaluating the relative bands as ‘trace
quantity value’ (o.d. · mm of each band) by Quantity-One
4·3 software in the Fluor-S gel analyzer (Bio-Rad Labs,
Hercules, CA, USA).
Statistical analyses
Mean values of cellular subsets and phenotype expression
between groups were compared by Student’s t-test and,
in several instances, by the Wilcoxon test as a nonpara-
metric method.
Results
Nef induces a variable proliferation on PBL
Since Nef has been consistently reported to suppress T
cells [16,20,21], we first assessed the extent of apoptosis
in PBL cultures from both HIV-1-infected patients and
healthy controls after 60 h of incubation with the nef-
3T3–7 transfectant. An apparent inhibition of apoptosis
was noted in both groups of cultures. Nef induced a
variable though significant decrease in the relative extent
of the mean subdiploid DNA peaks (M1 6 SD): 14·2 6 5%
and 10·7 6 3% in Nef-treated cultures, as compared to
32·4 6 4% and 19·6 6 3% in untreated cultures from
patients with severe (CD4þ # 300 mL¹1) and moderate
(> 300 mL¹1) lymphopenia (P <0·02 in both instances).
The control cultures from uninfected donors showed a
similar, though lower decline of apoptosis: mean M1
8·7 6 3% in Nef-stimulated vs. 14·6 6 3 in untreated
cultures. However, this variation was not different in a
statistical mode (P >0·2). These data are in agreement,
and were in apparent concordance with reference values
from our previous work [32], though the prolonged xeno-
antigen stimulation by 3T3 cells in increasing the PBL
apoptosis independently of Nef cannot be excluded. Repre-
sentative profiles of this down-modulated apoptosis in a
patient with severe CD4þ lymphopenia (Pt. # 1) and
a control subject are shown in Fig. 1. In both instances,
the subdiploid DNA cell population was quantitatively
reduced in cells harvested after incubation with the 3T3–
7 clone (right panels). Morphological features of cell
activation and proliferation, namely the expansion of both
size and forward scatters, were also evident in both the
euploid and the hyperdiploid cell populations gated in
M2 and M3, respectively. These individual variations of
fluorescence intensity were not statistically evaluated,
though they were clearly detected in cells cultured in the
presence of Nef and occurred in most preparations.
Further experiments were addressed to identify the
cellular subset(s) with a prominent tendency to proliferate.
Double fluorescence flow cytometry was used to measure
Ki67 expression in CD16þ, CD4þ and CD8þ subsets
Q 1999 Blackwell Science Ltd, European Journal of Clinical Investigation, 29, 980–991
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Figure 1 Variation of ploidy in PBL from a severely
lymphopenic HIV-1 patient and a normal donor after 60 h of
incubation in the presence of myristoylated Nef protein of HIV-1
exposed by the membrane of transfected 3T3–7 fibroblasts
(right panel). This treatment usually reduced M1 peak
corresponding to the extent of the subdiploid DNA content in
apoptotic cells as compared to the control culture with
untransfected fibroblasts (left panel). By contrast, M2
(euploid cells) and M3 (hyperdiploid cells) populations were
proportionally increased. The pattern is representative of most
cultures from patients where inhibition of apoptosis reflected
the relative tendency to proliferate.
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following a 60-h-culture with Nef. Table 1 shows the
distribution of relative values of peripheral CD4þ and
CD8þ cell counts in association with the effect of Nef
in groups of cultures from patients and controls. Nef
generally had little effect on the proliferation of CD16þ
and CD4þ cells, because their mean values within each
group showed a decrease, thus suggesting an apparent
suppression. On comparing single values within each
subset, however, it was found that patients with severe
lymphopenia were variably affected in relative CD4þ cell
proliferation. Similarly, a proliferative decrease was prevalent
in the uninfected controls and the mean values of suppression
were significant (P<0·02), thus confirming the susceptibility
of uninfected cells to Nef-induced apoptosis [17,21]. In
contrast, a clear-cut trend to proliferation was detected
in the CD8þ subset. The increase of positive cells was
higher in patients than in the controls and the difference
between mean values was significant (P< 0·05 in both
instances) in each group. We also recorded a moderate
Q 1999 Blackwell Science Ltd, European Journal of Clinical Investigation, 29, 980–991
Table 1 Peripheral levels of CD4þ and CD8þ cells and variation of Ki67 antigen expression on specific T-cell subsets after 60-cultures
of PBL in the presence of Nef expressed by the membrane of 3T3-7 transfected fibroblasts as layer (Nef-treated) compared to control
cultures using untransfected cells (control). Significant variations included an increase of the Ki67 expression in CD8þ subset from
both groups of patients with severe as well as moderate CD4þ lymphopenia (P<0.05 in both instances). In addition, a slight though
significant decrease of CD4þ subset was also observed in cultures from control donors (P<0.02)
Peripheral levels
(cells mL¹1) Per cent expression of Ki67 antigen on T-cell subsets
CD16 CD4 CD8
CD4 CD8 control Nef-treated control Nef-treated control Nef-treated
HIV-1þ patients
(a) Severely lymphopenic (#300 CD44 cells mL¹1)
Patient:
1 167 483 8.2 7.8 6.2 3.5 15.8 29.8
2 206 471 6.4 5.8 12.3 10.4 21.1 26.4
3 188 290 6.5 6 9.8 9 18.7 21.6
4 47 368 3.1 2.4 7.1 5 19 32.3
5 109 409 3.5 2.6 8.3 4.1 19.6 34.4
6 28 421 2.1 1.8 5.4 4.8 21.5 29.6
7 95 287 8.3 9 11.4 9.6 20.4 24.1
M 6 SD 5.4 6 2 5 6 2 8.6 6 2 6.6 6 2 19.4 6 1 28.3 6 4
(b) Moderately lymphopenic (>300 CD4þ cells mL¹1)
Patient:
8 539 901 9.5 10.2 12.3 10.6 31.8 43.6
9 421 1,080 13.4 11.2 22.6 21.4 30.4 36.2
10 406 780 10.4 8 18.4 20.2 26.5 31.5
11 605 980 14.5 15.2 20.1 16.3 19.4 24.3
12 427 1,010 11.6 10 17.4 16.5 30 31.4
13 705 1,606 9.6 8.5 21.3 20.4 28.4 41.5
14 578 865 11.1 10 15.2 14.1 26.4 36.2
15 335 820 7.3 6.1 11 9.2 30.5 38.5
16 390 680 8.7 9.5 9.6 8 21.3 28
M 6 SD 10.6 6 2 9.8 6 2 16.4 6 4 15.1 6 4 27.1 6 2 34.5 6 6
Normal donors (ND):
1 1,780 792 11 8.6 26.4 20.3 15.6 16.3
2 2,010 900 15.4 15.1 31.3 28.4 21.4 23.6
3 2,300 980 7.8 6.5 28 21.5 18.8 20.4
4 1,950 970 10 8.7 34.1 30.6 21.2 22.4
5 2,600 1,270 13.4 8.4 36.6 19.4 29.4 31.2
6 1,870 1,085 9.5 8.2 42.1 26 13.6 15.6
7 2,300 980 7.8 6.5 28 21.5 18.8 20.4
8 2,900 1,450 12.4 11.6 40.2 36.4 28.4 29.9
9 1,870 906 11.8 12.1 30.4 26.3 21.8 23
M 6 SD 11 6 2 9.5 6 2 33 6 5 25.6 6 5 21 6 5 22.5 6 5
Figure 2 Cytofluorimetric evaluation of changes in the size of
CD8þ/CD57þ subset in HIV-1þ patients with and without
severe lymphopenia (peripheral CD4þ cells <300 mL¹1) and in a
normal subject. The fluorescence profiles are related to single
subjects and show representative patterns for each group of
cultures. Incubation of PBL in the presence of Nef (right panels)
induced a major subset growth in cultures from lymphopenic
patients, as in section (a), and a poor increase in those from
nonlymphopenic patients (b) and healthy controls (c). Left
panels refer to control cultures prepared with untransfected
fibroblasts.
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though not significant tendency to proliferation (P>0·1) in
cultures from healthy controls.
A major proliferative effect is detectable in
CD8þ/CD57þ cells
Additional phenotyping tests identified the CD8þ subsets
sensitive to Nef. The effect of Nef on the CD8þ/CD57þ
subset, which displays a suppressor phenotype, was investi-
gated by measuring the extent of the double positive CD8þ/
CD57þ subset on harvested PBLs from all cultures. An
apparent increase in the percentage of these cells was
observed in most Nef-stimulated patient cultures from
patients showing the proliferative trend by Ki67 expression.
Major elevations of CD8þ/CD57þ cells (100% of increase)
occurred prevalently in Nef-stimulated cultures from the
severely CD4þ lymphopenic patients (P <0·01). In fact,
the mean value of 16·8 6 4% of CD8þ/CD57þ cells in
cultures from this group rose to 35·1 6 6% after incubation
with Nef. Cell cultures from nonlymphopenic patients
also showed a slight increment of mean levels (24·6 6 3%
vs. 20·3 6 7% in unstimulated cultures), whereas no
evident variations were observed in the control cultures
from the uninfected donors (10·9 6 2% vs. 9·8 6 3% of
CD8þ/CD57þ cells in unstimulated cultures). Figure 2
compares representative profiles from a severely lympho-
penic (patient no. 4), a nonlymphopenic patient (patient
no. 15) and a control donor (normal donor no. 1): the
CD8þ/CD57þ increase was doubled in the first patient,
whereas it was small in the second. The pattern relative
to the control shows that Nef has little effect on CD8þ/
CD57þ population in cultures from healthy donors. These
data suggested that Nef stimulation results in greater
expansion of suppressor CD8þ cells when CD4þ cells are
severely depleted as in the advanced stages of HIV-1
infection.
Nef down-regulates Fas-L expression in cytotoxic
CD8þ cells from HIV-1-infected patients
We next looked to assess whether or not Nef was able to
affect the CD8þ cells displaying the cytolytic phenotype
(CTL). Fas-L expression was then explored in these cells
by measuring the relative mRNA levels of purified CD8þ
cells from most patient cultures, five patients with severe
and six with moderate lymphopenia. In addition, CD8þ
cells were harvested from the cultures of five healthy
controls. We observed an apparent diminution of the
Fas-L bands in Nef-exposed CD8þ cells from all culture
samples. Figure 3 illustrates this pattern in a representative
subject from each group, namely from patients no. 4 and
15, and normal donor no. 6. The quantitative evaluation
by the Fluor-S analyzer confirmed a general decrease
of Fas-L expression after treatment with Nef (lanes b).
We found a difference in the Fas-L mRNA trace quantity
values, which were apparently higher in patients with
severe CD4þ lymphopenia (0·112 of mean reduction
value as compared to 0·087 o.d. · mm of the other group
of patients). However, these variations were not statistically
evaluated in comparing groups of samples because of the
high intragroup variability.
Suppressor anti-HIV-1 CD8þ lymphocytes are
inhibited by Nef
Lastly, the role of Nef on noncytotoxic HIV-1-specific
suppressor CD8þ lymphocytes in cultures from HIV-1-
infected subjects was examined. This anti-HIV-1 response
appears to be associated primarily with activated CD8þ
cells expressing both HLA-DR and CD28 antigens and
acts through a soluble inhibitory factor termed CAF
(CD8þ T-cell antiviral factor) [33]. Therefore, our analysis
investigated the effect of Nef on this specific subset by
measuring in double fluorescence the expression of
HLA-DR molecules in purified CD8þ cells from four
patients with severe and 5 with moderate lymphopenia.
Nef down-regulated HLA-DR in most cultures. Patients
with the lowest CD4þ levels showed a significant suppres-
sion of their CD8þ/HLA-DRþ population in response
to Nef: the mean number declined from 32·9 6 8 to
15·1 6 7 (P<0·02). A similar effect was also observed
in single patients with moderate CD4þ lymphopenia.
However, although the decrement of the mean value of
HLA-DRþ cells ranged from 37·6 6 4% in untreated
cultures to 32·1 6 6% in the presence of Nef, it was not
statistically significant (P> 0·2).
Figure 4 reports the cytofluorimetric pattern of two
patients from each group and gives an example of the
suppressive effect of Nef on these cells, which was higher
than 50% in the CD8þ population of both patients with
severe CD4þ lymphopenia (section a). Similarly, a lower
suppression of proliferation was demonstrable in both
patients with moderate lymphopenia (section b), whose
average value was about 5%, and reflected the results
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Figure 3 Comparative PCR amplification of Fas-L mRNA in
CD8þ cells purified from cultures stimulated by Nef (lane b)
with respect to unstimulated cultures (lane a). The treatment
down-regulated Fas-L mRNA in all instances, particularly in
patients with severe CD4þ lymphopenia (patient no. 4 is
representative of this group).
Figure 4 Representative patterns of cytofluorimetric assays
related to quantitative variations of activated (HLA-DRþ) CD8þ
cells in cultures from patients with severe (a) and moderate (b)
lymphopenia in response to 60 h of incubation with Nef. This
treatment induced a substantial decrease in this subset, especially
in patients with advanced disease.
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of other patients with similar CD4þ cell levels. Lastly,
Table 2 includes the variations of mean values in fluores-
cence intensity of DR expression following treatment
with Nef. In most instances we observed a variable
suppression of DR antigens in CD8þ cells incubated with
Nef. However, such variations of relative fluorescence
intensity in DR expression were not calculated in statis-
tical terms because of the small number of samples. These
results suggested that activated anti-HIV-1 suppressor
CD8þ cells could be directly inhibited by Nef in culture.
Discussion
Our study on the effect of Nef on CD8þ cells during HIV-1
infection has shown that, in addition to its cytolytic effect
on other T cells, it stimulates the growth of CD8þ/CD57þ
subset in vitro, and down-modulates both the expression of
Fas-L, a death factor of CTLs, and the proliferation of CD8þ
cells activated to HIV-1; namely the CD8þ/HLA-DRþ
subset. These immune dysfunctions of CD8þ cells are
significant in patients with severe lymphopenia and probably
contribute to the progression of HIV-1 infection to AIDS.
Recent work has provided new insights into the function
of Nef during HIV-1 disease. Originally seen as a negative
regulator for virus replication [9] it is now being shown
to play a positive role in replicating HIV-1 in primary T
cells and T-cell lines [34–36]. It also down-regulates cell
surface levels of CD4 molecules [37,38] and induces
cytolysis of CD4þ cells in either its soluble [21] or its
myristoylated form [20,24]. Although the myristoylated
Nef peptide is anchored on the internal sheet of the
plasma membrane by the N-terminal glycine, the myris-
toylation procedure induces a disordering effect on the
lipid bilayers, resulting in nonlamellar phases of the whole
membrane layer and extrusion of the other terminal por-
tion of the viral protein [39] [40]. Exhibition of the
carboxy-terminal domain of Nef on the HIV-1-infected
T-cell surface is critical in provoking cell death by cytotoxi-
city in uninfected CD4þ lymphocytes [5,24], whereas
interaction of Nef with specific cellular kinases has sug-
gested that it interferes with signalling pathways that
promote T-cell activation [41].
Our present study emphasizes that, in contrast with the
down-regulation of CD16þ and CD4þ cells, the myristoy-
lated form of Nef from nef-3T3–7 transfectant induces
a number of functional defects within the CD8þ subset
that may promote the escape of both HIV-1 and infected
cells from immune control. However, as it has been repor-
ted that soluble Nef may affect proliferation of CD4þ cells
[21], further cellular suppression by soluble Nef mole-
cules possibly released in our cultures by either trans-
fected fibroblasts or infected cells cannot be ruled out.
The first derangement induced by Nef concerns the
increase of CD8þ/CD57þ cells. This subset is pheno-
typically distinct because of its prevalent suppression of
B-cell differentiation, proliferation and Ig secretion
[42,43]. Although no specific antiviral cytotoxicity has
been attributed to this population [44], its oligoclonal
expansion occurs in several clinical conditions including
cytomegalovirus infection [45], Crohn’s disease [46],
common variable immunodeficiency [47], and HIV-1
infection [48]. In this disease as well as in the immune
deficiency of bone marrow transplantation recipients [49],
suppression was related to a 20-kDa, heat-stable suppres-
sor factor [50] that inhibits lectin-driven proliferation
and cytolysis [51]. In our study, we observed that a broad
expression of Ki67 antigen was presented by CD8þ cells
cultured in the presence of Nef and paralleled the expan-
sion of the CD57þ cell subset, in particular in patients
with severe CD4þ lymphopenia. By contrast, mostly stable
or weakly increased values of CD57þ cells were detected
in cultures from moderately lymphopenic patients and
the controls. We interpreted the differential proliferative
response to Nef as a result of the divergent levels of CD4þ
cells in vivo. As patients with AIDS or severe lymphopenia
have a minimal expression of the myristoylated protein
on infected CD4þ cells as a result of critical lymphocyte
depletion, exposure of their PBL to the high virus antigen
load as provided by nef-3T3–7 cells could have resulted in
a major stimulation and growth of the CD57þ population.
Q 1999 Blackwell Science Ltd, European Journal of Clinical Investigation, 29, 980–991
Table 2 Variation of relative fluorescence intensity of HLA-DR antigen expression in CD8þ cells from
HIV-1þ patients after their culture in the presence of Nef
Index of HLA-DR expression on CD8þ cells*
HIV-1þ Patient Untreated culture Nef-treated cultures
Severely lymphopenic 1 9.81 6.27
3 12.33 5.11
4 11.85 6.98
6 8.42 4.13
Moderately lymphopenic 9 10.42 9.5
10 8.52 8.31
12 11.45 10.18
14 9.47 6.53
15 7.51 6.18
*The HLA-DR expression index was defined as the ratio of mean fluorescence channels (specific
MoAb/isotype-matched control MoAb).
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Our study also points to the down-regulation of
Fas-L expression in cytotoxic CD8þ cells treated with
Nef. Fas-L is the functional coreceptor of Fas and induces
apoptosis in Fasþ target cells by oligomerization of the
receptor. This mechanism is used by most effector cells
and Fas-L is considered a major phenotypic marker of
CTLs. The apparent down-modulation of mRNA in
treated cells in our study was in line with the relative
increase of the CD57þ subset, especially in patients with
severe lymphopenia. As Nef-induced cytolysis of unin-
fected lymphocytes is independent of Fas/Fas-L system
[26,27], this finding supports the view that the viral protein
does not act through the Fas/Fas-L pathway. On the other
hand, similarly defective Fas-L mRNA expression has
been described in advanced HIV-1 infection [52–54],
suggesting that the antigenic charge of soluble Nef may
partly contribute to Fas-L down-regulation, though defec-
tive CTL function in this disease could be the result of
the increased suppression by CD57þ cells [45,48]. Our
study, in fact, documented CD57þ expansion in advanced
infection following exposure to Nef, though its suppression
of Fas-L via other mechanisms cannot be excluded.
Another interesting finding was the detrimental effect
of Nef on HIV-1 suppressor CD8þ lymphocytes resulting
in a defective expression of HLA-DR molecules. These
data are in apparent contrast with the increase of Ki67þ
cells within the same subset. However, previous studies
have pointed out a possible discrepancy between both
cell cycle and activation antigen expression in CD4þ and
CD8þ T cells in patients receiving the HAART (highly
active antiretroviral treatment) therapy, especially during
the chronic HIV-1 infection [55] [56]. In particular,
though in the presence of a proliferative trend involving
the total T-cell population, activation of CD8þ T cells
measured by both CD38 and HLA-DR expression was
significantly affected in this subset [57]. Our results show-
ing a similar inhibition of HLA-DR molecules in response
to Nef in patients with advanced disease are in line with
these observations. On the other hand, CD8þ cells expres-
sing both HLA-DR and CD28 markers are thought to
suppress HIV-1 replication by CAF in CD4þ lymphocytes
and macrophages [33]. We observed an evident decline of
this population in cultures treated with Nef. Suppression
of HIV-1 replication by CAF in naturally or acutely infec-
ted CD4þ cells has been described as dose-dependent
and correlated with clinical state and CD4þ cell levels in
peripheral blood [58]. Although we did not measure
the extent of CAF secretion in cultures, the depletion
of HLA-DRþ cells after incubation with Nef suggests a
parallel reduction in the release of the suppressive factor,
particularly in patients with advanced disease.
Our data on the effect of Nef on CD8þ cells support
recent studies describing its multifactorial role in the
depletion of immune cells during HIV-1 infection. In
addition to its cytolysis of uninfected CD4þ lymphocytes,
Nef may down-regulate the MHC class I on infected
cells to promote their escape from cytolysis of functional
CTLs [59]. In this context, its down-modulation of their
expression of Fas-L and its inhibition of suppression by
non cytotoxic anti-HIV-1 CD8þ cells are ways of escap-
ing immune surveillance. Additional work is required to
investigate the molecular defects of such Nef-related
deregulations of CD8þ cells, though they may be the
multiple outcome of a single deviation primarily induced
by either soluble or myristoylated Nef. For instance, altera-
tion in the secretion of CD8þ cell cytokines could be a
primary event leading to differentiated dysfunctions within
the subset. Preliminary data from our laboratory support
this hypothesis, in that CD8þ/CD57þ cells treated with
Nef showed high mRNA expression of several suppressive
cytokines, including IFN-g and IL-4, which could signifi-
cantly influence both Fas-L expression in CTLs and CAF
secretion in activated CD8þ cells.
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